CytRx Corp (CYTR) Announces INNO-206 Combination Therapy Could Reduce Toxicity and Improve Tumor Response
Tweet
Share
E-mailGet Alerts CYTR Hot Sheet
Join SI Premium – FREE
CytRx Corporation (Nasdaq: CYTR) today announced the achievement of complete remissions in aggressively growing in vivo ovarian cancer tumors treated with a combination of low doses of CytRx’s tumor-targeted albumin-binding doxorubicin conjugate INNO-206 and the commonly prescribed cancer treatment doxorubicin.
Study results were published in peer-reviewed Journal Investigational New Drugs.
Study results were published in peer-reviewed Journal Investigational New Drugs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- CoVolt Power files for proposed IPO
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
